II. Indications
- FDA Approved
- Hodgkin Lymphoma (stage 3-4, MOPP Protocol)
- Off-Label
- Non-Hodgkin Lymphoma
- Cutaneous T-Cell Lymphoma
- CNS Neoplasms (advanced disease, e.g. glioblastoma multiforme)
III. Mechanism
- See Alkylating Agent
- Triazene alkylating antineoplastic (Methylhydrazine derivative) active in the S phase of the cell cycle (DNA duplication)
- Inhibits trans-methylation of Methionine into Transfer RNA, blocking Protein synthesis
- As an Alkylating Agent, also forms cytotoxic free radicals which damage DNA
IV. Medications
- Capsule: 50 mg
V. Dosing
- See other references for disease specific dosing protocols
VI. Adverse Effects
- Bone Marrow Suppression
- Secondary Malignancy
- Hemolysis (with RBC Heinz bodies)
- Impaired future fertility
- Alopecia
- Hypersensitivity
- Neurologic effects (children)
VII. Safety
- Avoid in Lactation
- Avoid in Pregnancy (all trimesters)
- Use reliable Contraception
- Monitoring
VIII. Drug Interactions
- High Tyramine Intake
- Risk of Hypertensive Emergency
-
Alcohol
- Disulfiram reaction
- Procarbazine decreases other drug levels
- Procarbazine increases other drug levels
IX. Resources
X. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia